TransMed Systems, Inc. Names Carla Balch CEO and Bolsters Future Growth with Key Executive Hires

Balch is an experienced chief executive, building infrastructure and growth in healthcare technology by spearheading pioneering oncology software. Previously, Carla served as President of NantCare, an oncology clinical trial and technology company. As president and CEO of Altos Solutions, a $15M web-based oncology electronic medical record and big data company, she led its sale to Flatiron Health, a Google-Ventures backed organization recently acquired by Roche for $2B. Carla developed a passion for patients and technology as an executive at an oncology research company and community research network formed at West Cancer Center in Memphis, TN.

Additionally, the company named Jeff Edenfield, MD, as its first Chief Medical Officer. Dr. Edenfield currently serves as Associate Professor at University of South Carolina’s School of Medicine—Greenville and is a treating oncologist. Widely published and active on numerous oncology and research boards, Dr. Edenfield’s extensive experience in the application of genomic information on patient care has driven a focus on enabling patients with access to quality clinical trials. He has specific interest in phase I drug development and initiated a respected rare tumor program with emphasis on target identification and trial enrollment for the patients with the disease.

“The ability of TransMed to dramatically improve the process of developing clinical trials and giving access to clinical trials and research is in the hands of a very skilled, experienced and proven leader,” said John Lovitt, Chairman of the TransMed Systems’ board. “Under Carla’s leadership, and with the powerful, collaborative force she has assembled in her leadership team, the organization is well-positioned to grow and fulfill our promise of ensuring that everyone who needs it has access to a clinical trial.”

“I am incredibly proud of this passionate, smart and experienced team leading TransMed to its full potential of changing the trajectory of clinical trials,” said Balch. “Collaboration is key—not just with each other, but also with our customers and stakeholders. This team will deliver the expertise and teamwork required to achieve our goals and I am honored to lead them.”

The full leadership team, which also includes new hires life sciences, client engagement, sales, marketing and finance, is comprised of

• Jeff Edenfield, MD, Chief Medical Officer
• Deb Kientop, VP, Life Sciences
• Chris Mazzanti, SVP, Product Development
• Jim Reddy, VP, Client Engagement
• Jeremy Miller, Ph.D, Chief Technology Officer
• Frank DuPont, SVP of Professional Services
• Robert Robbins, VP, Sales
• Russ Clark, SVP, Business Development and Legal
• Dorit Baxter, SVP, Marketing
• Aaron Aylesworth, CPA, Corporate Controller

About TransMed

TransMed is a leading provider of technology, insights, and expertise that help harness the power of knowledge to dramatically improve the process of developing, identifying, and matching eligible patients to clinical trials. Powered by a vast oncology data consortium, a powerful clinical trial enablement platform, and people expertise, TransMed believes that no time can be wasted in advancing the ability to bring promising and lasting solutions to cancer and other critical illnesses. Our expert team, in collaboration with our partners, customers and Scientific Advisory Board, is passionate about delivering the technology to use when life depends on it—and improving the standard or care for patients everywhere.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005216/en/